simendan has been researched along with Arrhythmia in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aalto-Setälä, K; Gaballah, M; Kallio, P; Kreutzer, J; Mäki, AJ; Penttinen, K | 1 |
| Chen, SA; Chien, YS; Hsieh, YC; Huang, JL; Li, CH; Lin, JC; Lin, SF; Lin, YJ; Weng, CJ; Wu, SJ | 1 |
| Lu, YQ; Pan, J; Yang, YM; Zhu, JY | 1 |
| Huang, LQ; Huang, X; Jiang, RL; Lei, S; Xia, GL; Zhi, YH; Zhu, MF | 1 |
| Gams, E; Klocke, RC; Korbmacher, B; Meyer, K; Schipke, JD | 1 |
| Banach, M; Kowalczyk, M; Kozłowski, D; Lip, GY; Mikhailidis, DP; Rysz, J | 1 |
| Ata, N; Birdane, A; Cavuşoğlu, Y; Demirüstü, C; Göktekin, Ö; Görenek, B; Tek, M; Ünalır, A | 1 |
| Borlu, F; Dal, MS; Oztekin, E; Paksoy, F; Tursun, I; Ulaş, T | 1 |
| Leprán, I; Papp, JG | 1 |
| Pieske, B | 1 |
| Lehtonen, L; Lilleberg, J; Toivonen, L; Ylönen, V | 1 |
| Kaplinsky, EJ; Perrone, SV | 1 |
| Colucci, WS; De Luca, L; Gheorghiade, M; Massie, BM; Nieminen, MS | 1 |
| Papp, JG; Pollesello, P; Varró, AF; Végh, AS | 1 |
| Flevari, P; Kourea, K; Kremastinos, DT; Leftheriotis, D; Panou, F; Parissis, JT | 1 |
| Das, B; Sarkar, C | 1 |
| Adreanides, E; Athanasopoulos, G; Cokkinos, DV; Dritsas, A; Giamouzis, G; Mavrogeni, S; Panagiotakos, D; Papadopoulou, E; Spargias, K; Thomopoulou, S; Vassiliadis, I | 1 |
| Heffernan, D | 1 |
| Du Toit, EF; McCarthy, J; Muller, CA; Opie, LH | 1 |
| du Toit, E; Hofmann, D; McCarthy, J; Pineda, C | 1 |
5 review(s) available for simendan and Arrhythmia
| Article | Year |
|---|---|
Multiorgan Drug Action of Levosimendan in Critical Illnesses.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Critical Illness; Humans; Myocardial Contraction; Myocardium; Randomized Controlled Trials as Topic; Simendan | 2019 |
Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Comorbidity; Critical Illness; Dobutamine; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Hypotension; Pyridazines; Randomized Controlled Trials as Topic; Risk Factors; Simendan; Survival Rate; Treatment Outcome | 2013 |
Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties.
Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Randomized Controlled Trials as Topic; Simendan | 2010 |
Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan | 2005 |
Evidence-based use of levosimendan in different clinical settings.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiotonic Agents; Child; Heart Failure; Humans; Hydrazones; Intraoperative Care; Myocardial Ischemia; Pyridazines; Randomized Controlled Trials as Topic; Shock, Cardiogenic; Simendan | 2006 |
4 trial(s) available for simendan and Arrhythmia
| Article | Year |
|---|---|
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiotonic Agents; Dobutamine; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Parenteral; Male; Middle Aged; Pyridazines; Risk Factors; Simendan; Tachycardia, Ventricular; Ventricular Premature Complexes | 2010 |
[The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Topics: Aged; Arrhythmias, Cardiac; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Prospective Studies; Pyridazines; Simendan; Treatment Outcome | 2012 |
Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Output, Low; Cardiotonic Agents; Drug Administration Schedule; Echocardiography; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Hydrazones; Middle Aged; Mitral Valve Insufficiency; Myocardial Contraction; Pyridazines; Simendan; Stroke Volume; Surveys and Questionnaires; Systole; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
11 other study(ies) available for simendan and Arrhythmia
| Article | Year |
|---|---|
Cardiac Ischemia On-a-Chip: Antiarrhythmic Effect of Levosimendan on Ischemic Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cells, Cultured; Humans; Hypoxia; Induced Pluripotent Stem Cells; Ischemia; Lab-On-A-Chip Devices; Myocardial Ischemia; Myocytes, Cardiac; Simendan | 2022 |
Levosimendan attenuates electrical alternans and prevents ventricular arrhythmia during therapeutic hypothermia in isolated rabbit hearts.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Heart; Hypothermia, Induced; Rabbits; Simendan; Ventricular Fibrillation | 2023 |
Inotropic, vasodilating and preconditioning actions of levosimendan in the heart.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dose-Response Relationship, Drug; Heart; Hemodynamics; Hydrazones; In Vitro Techniques; Myocardial Reperfusion Injury; Myocardium; Oxygen Consumption; Potassium Channels; Pyridazines; Rabbits; Simendan; Vasodilator Agents | 2008 |
Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats.
Topics: Administration, Oral; Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Consciousness; Coronary Disease; Dose-Response Relationship, Drug; Electrocardiography; Heart; Heart Rate; Hydrazones; Male; Myocardial Ischemia; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan; Time Factors | 2003 |
Levosimendan in regional myocardial ischemia.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Arrhythmias, Cardiac; Cardiac Output; Cardiotonic Agents; Coronary Stenosis; Coronary Vessels; Cyclic Nucleotide Phosphodiesterases, Type 3; Heart Rate; Hemodynamics; Humans; Hydrazones; Myocardial Contraction; Myocardial Ischemia; Phosphodiesterase Inhibitors; Potassium Channel Blockers; Pyridazines; Regional Blood Flow; Simendan; Swine; Vasodilator Agents; Venous Pressure | 2002 |
The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Finland; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction; Probability; Pyridazines; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Simendan; Treatment Outcome | 2004 |
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Coronary Vessels; Dogs; Electrophysiology; Female; Heart Ventricles; Hemodynamics; Hydrazones; Male; Milrinone; Myocardial Reperfusion Injury; Pyridazines; Simendan; Ventricular Function | 2006 |
Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model.
Topics: Adenosine Triphosphate; Anesthesia; Animals; Arrhythmias, Cardiac; Blood Pressure; Heart Rate; Hydrazones; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Nitric Oxide; Nitric Oxide Synthase Type II; Potassium Channels; Pyridazines; Rabbits; Simendan | 2007 |
Inoprotection review.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Hydrazones; Oxygen Consumption; Pyridazines; Simendan | 2008 |
Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Agonists; Calcium Channel Blockers; Cyclic AMP; Cyclic GMP; Dobutamine; Glyburide; Guinea Pigs; Heart; Hydrazones; In Vitro Techniques; L-Lactate Dehydrogenase; Lactic Acid; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Nucleotides, Cyclic; Phosphocreatine; Pyridazines; Simendan; Stereoisomerism | 1999 |
Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Coronary Circulation; Coronary Disease; Hydrazones; Male; Models, Animal; Myocardial Contraction; Pyridazines; Regional Blood Flow; Simendan; Swine; Vascular Resistance | 2001 |